We could demonstrate that activation of ERβ, achieved by treating the cells with E2 or ERβ subtype-selective agonists (the classical ERβ agonist, DPN, or more recently synthesized agonists, KB1, KB2, and KB4) significantly decreased BLM melanoma cell proliferation. This evidence concerns the gene ESR2 and melanoma.